[{"orgOrder":0,"company":"Pharming","sponsor":"Pharming","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Conestat Alfa","moa":"Plasma protease C1 inhibitor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharming \/ Pharming","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Pharming"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Conestat Alfa","moa":"Plasma protease C1 inhibitor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0.02,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"CMIC Co, Ltd. Japan | LabCorp | Fortrea | Aixial Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Undisclosed","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Pharming \/ CMIC Co, Ltd. Japan | LabCorp | Fortrea | Aixial Group","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ CMIC Co, Ltd. Japan | LabCorp | Fortrea | Aixial Group"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Abliva","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"KL1333","moa":"NAD","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Pharming","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.070000000000000007,"dosageForm":"Oral Tablet","sponsorNew":"Pharming \/ Pharming","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Pharming"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Lahey Hospital & Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Lahey Hospital & Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Lahey Hospital & Medical Center"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Conestat Alpha","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharming \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"Pharming","sponsor":"CMIC Co, Ltd. Japan | LabCorp | Fortrea | Aixial Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Undisclosed","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharming \/ CMIC Co, Ltd. Japan | LabCorp | Fortrea | Aixial Group","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ CMIC Co, Ltd. Japan | LabCorp | Fortrea | Aixial Group"},{"orgOrder":0,"company":"Pharming","sponsor":"LabCorp | Axial Biotech | CMIC Co, Ltd. Japan","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Undisclosed","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharming \/ LabCorp | Axial Biotech | CMIC Co, Ltd. Japan","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ LabCorp | Axial Biotech | CMIC Co, Ltd. Japan"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Conestat Alfa","moa":"Plasma protease C1 inhibitor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Conestat Alpha","moa":"C1 esterase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"OTL-105","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Pharming","amount2":0.20999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Pharming \/ Pharming","highestDevelopmentStatusID":"4","companyTruncated":"Pharming \/ Pharming"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Conestat Alpha","moa":"C1 esterase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Pharming
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
